-$0.46 Earnings Per Share Expected for Corvus Pharmaceuticals Inc (CRVS) This Quarter
Brokerages expect that Corvus Pharmaceuticals Inc (NASDAQ:CRVS) will post ($0.46) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Corvus Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.45) and the lowest estimate coming in at ($0.47). Corvus Pharmaceuticals posted earnings of ($0.62) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 25.8%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 1st.
According to Zacks, analysts expect that Corvus Pharmaceuticals will report full year earnings of ($1.98) per share for the current financial year, with EPS estimates ranging from ($2.02) to ($1.94). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.79) per share, with EPS estimates ranging from ($1.88) to ($1.70). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Corvus Pharmaceuticals.
Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings results on Thursday, August 2nd. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.24.
Several hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in shares of Corvus Pharmaceuticals by 16.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 156,471 shares of the company’s stock worth $1,718,000 after acquiring an additional 22,035 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Corvus Pharmaceuticals by 51.9% during the 2nd quarter. BlackRock Inc. now owns 1,119,507 shares of the company’s stock worth $12,290,000 after acquiring an additional 382,389 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Corvus Pharmaceuticals by 48.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 25,900 shares of the company’s stock worth $285,000 after acquiring an additional 8,400 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Corvus Pharmaceuticals by 35.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 37,099 shares of the company’s stock worth $407,000 after acquiring an additional 9,782 shares in the last quarter. Finally, Rhumbline Advisers purchased a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter worth about $147,000. 86.65% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:CRVS traded down $0.05 during mid-day trading on Friday, hitting $9.37. The company’s stock had a trading volume of 31,726 shares, compared to its average volume of 70,484. Corvus Pharmaceuticals has a 1 year low of $7.42 and a 1 year high of $17.64.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Further Reading: What does EPS mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.